Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Cephalon )
ClinicalTrials.gov Identifier:
NCT00233675
First received: September 27, 2005
Last updated: May 8, 2014
Last verified: May 2014

September 27, 2005
May 8, 2014
August 2003
February 2005   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00233675 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder

To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).

Not Provided
Interventional
Phase 3
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
General Anxiety Disorder
Drug: GABITRIL (tiagabine hydrochloride; CEP-6671)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
February 2005   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Not Provided
Not Provided
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00233675
C6671A/301/AX/US
Not Provided
Teva Pharmaceutical Industries ( Cephalon )
Cephalon
Not Provided
Study Director: Charles Brown, MD Cephalon
Teva Pharmaceutical Industries
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP